US Court denies appeal in Baraclude patent case

13 June 2014

US pharma major Bristol-Myers Squibb (NYSE:BMY) yesterday announced that the US Court of Appeals for the Federal Circuit has denied the company’s appeal of a February 2013 ruling by the US District Court for the District of Delaware that found the patent covering the company’s hepatitis C drug Baraclude (entecavir), US patent 5,206,244 invalid.

The patent had been challenged by Israel-based Generics giant Teva Pharmaceutical Industries (NYSE: TEVA). B-MS said it is reviewing the decision and considering all its legal options.

Teva’s Abbreviated New Drug Application for entecavir has received tentative approval from the US Food and Drug Administration Teva will finalize the launch plans for this product once it receives final approval from the FDA.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK